Literature DB >> 10734223

Structure-function relationships of the NMDA receptor antagonist peptide, conantokin-R.

T Blandl1, S E Warder, M Prorok, F J Castellino.   

Abstract

Conantokin-R (con-R) is a gamma-carboxyglutamate-containing 27-residue neuroactive peptide present in the venom of Conus radiatus, and acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. This peptide features a single disulfide bond, a type of structural element found in most classes of conotoxins, but not in other conantokins. The NMDA receptor antagonist activity of chemically synthesized con-R was determined through an assay involving inhibition of the spermine-enhanced binding of the NMDA receptor channel blocker, [(3)H]MK-801, to rat brain membranes, and yielded an IC(50) of 93 nM. This value represents a 2-5 times better potency than con-G or con-T, the other two characterized conantokins. Circular dichroism (CD) analysis of the metal-free form of con-R is indicative of a low alpha-helical content. There is an increase in alpha-helicity upon the addition of divalent cations, such as Ca(2+), Mg(2+), or Zn(2+). Isothermal titration calorimetry experiments showed one detectable Mg(2+) binding site with a K(d) of 6.5 microM, and two binding sites for Zn(2+), with K(d) values of 150 nM and 170 microM. Residue-specific information of the conformational state of con-R was obtained by two-dimensional (1)H-NMR. Analyses of the alpha-proton chemical shifts, NOE patterns, and hydrogen exchange rates of the peptide indicated an alpha-helical conformation for residues 1-19. Synthetic con-R-derived peptide variants, containing deletions of 7 and 10 amino acid residues from the carboxy-terminus of the wild-type peptide, displayed unaltered cation binding and NMDA receptor antagonist properties. The alpha-helical secondary structures of the two truncation peptides were more stable than full-length con-R, as evidenced by CD measurements and reduced backbone hydrogen exchange rates. These results provide experimental evidence that the structural elements common to the three conantokins thus far identified are the primary determinants for receptor function and cation binding/secondary structure stability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10734223     DOI: 10.1016/s0014-5793(00)01309-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

Review 1.  Marine pharmacology in 2000: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and antiviral activities; affecting the cardiovascular, immune, and nervous systems and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Mark T Hamann
Journal:  Mar Biotechnol (NY)       Date:  2003-11-03       Impact factor: 3.619

2.  From molecular phylogeny towards differentiating pharmacology for NMDA receptor subtypes.

Authors:  Randall J Platt; Kigen J Curtice; Vernon D Twede; Maren Watkins; Paweł Gruszczyński; Grzegorz Bulaj; Martin P Horvath; Baldomero M Olivera
Journal:  Toxicon       Date:  2014-02-07       Impact factor: 3.033

3.  Specific determinants of conantokins that dictate their selectivity for the NR2B subunit of N-methyl-D-aspartate receptors.

Authors:  Z Sheng; M Prorok; F J Castellino
Journal:  Neuroscience       Date:  2010-08-03       Impact factor: 3.590

4.  Subtype-selective antagonism of N-methyl-D-aspartate receptor ion channels by synthetic conantokin peptides.

Authors:  Zhenyu Sheng; Qiuyun Dai; Mary Prorok; Francis J Castellino
Journal:  Neuropharmacology       Date:  2007-05-10       Impact factor: 5.250

5.  Conantokin-Br from Conus brettinghami and selectivity determinants for the NR2D subunit of the NMDA receptor.

Authors:  Vernon D Twede; Russell W Teichert; Craig S Walker; Paweł Gruszczyński; Rajmund Kaźmierkiewicz; Grzegorz Bulaj; Baldomero M Olivera
Journal:  Biochemistry       Date:  2009-05-19       Impact factor: 3.162

6.  Bioactive marine drugs and marine biomaterials for brain diseases.

Authors:  Clara Grosso; Patrícia Valentão; Federico Ferreres; Paula B Andrade
Journal:  Mar Drugs       Date:  2014-05-02       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.